(Q33376981)

English

A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

medulloblastoma

0 references

Brainstem glioma

1 reference

based on heuristic

inferred from title

1

object named as

Maryam Fouladi

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

H Stacy Nicholson

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Tianni Zhou

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Fred Laningham

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kathleen J Helton

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Emi Holmes

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kenneth Cohen

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Rose Anne Speights

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

John Wright

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ian F Pollack

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Children's Oncology Group

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

1 December 2007

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

110

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2535-2541

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Improving survival in recurrent medulloblastoma: earlier detection, better treatment or still an impasse?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

21 January 2018

Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

21 January 2018

Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

21 January 2018

Response of recurrent medulloblastoma to low-dose oral etoposide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of the treatment of children with recurrent gliomas with lomustine and vincristine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Overexpression of N-ras oncogene and epidermal growth factor receptor gene in human glioblastomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Application of signal transduction inhibition as a therapeutic strategy for central nervous system tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Actin' up: RhoB in cancer and apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Posttranslational modification of proteins by isoprenoids in mammalian cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Pediatric high-grade glioma: molecular genetic clues for innovative therapeutic approaches

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular genetic changes in a series of neuroepithelial tumors of childhood

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Ras inhibitors and radiation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23078

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.23078

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33376981&oldid=1981744458"